相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Biological Agents Involved in Malignant Mesothelioma: Relevance as Biomarkers or Therapeutic Targets
S. Crispi et al.
CURRENT CANCER DRUG TARGETS (2010)
Synergistic effect of gefitinib and rofecoxib in mesothelioma cells
Daniela Stoppoloni et al.
MOLECULAR CANCER (2010)
Malignant pleural mesothelioma: Genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets
Oluf Dimitri Roe et al.
LUNG CANCER (2010)
Identification of Potential Therapeutic Targets in Malignant Mesothelioma Using Cell-Cycle Gene Expression Analysis
Solange Romagnoli et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Global Gene Expression Profiling Of Human Pleural Mesotheliomas: Identification of Matrix Metalloproteinase 14 (MMP-14) as Potential Tumour Target
Stefania Crispi et al.
PLOS ONE (2009)
p21 in cancer: intricate networks and multiple activities
Tarek Abbas et al.
NATURE REVIEWS CANCER (2009)
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications
Kenji Ishitsuka et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations
Enrico P. Spugnini et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2008)
被撤回的出版物: Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability (Retracted article. See vol. 20, 2022)
Alessandra Verdina et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability
Alessandra Verdina et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma
Gavin J. Gordon et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Targeted Therapies in Breast Cancer: Established Drugs and Recent Developments
Jeanett Fischgraebe et al.
CURRENT CLINICAL PHARMACOLOGY (2008)
Opinion - Survivin, cancer networks and pathway-directed drug discovery
Dario C. Altieri
NATURE REVIEWS CANCER (2008)
oneChannelGUI: a graphical interface to Bioconductor tools, designed for life scientists who are not familiar with R language
Remo Sanges et al.
BIOINFORMATICS (2007)
The farnesyltransferase inhibitor R115777 (ZARNESTRA®) enhances the pro-apoptotic activity of interferon-α through the inhibition of multiple survival pathways
Michele Caraglia et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests
Kwang Woon Kim et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2 interaction
Koji Okamoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma
Enrico P. Spugnini et al.
CLINICAL CANCER RESEARCH (2006)
HURP is a ran-importin β-regulated protein that stabilizes kinetochore microtubules in the vicinity of chromosomes
HHW Silljé et al.
CURRENT BIOLOGY (2006)
affylmGUI: a graphical user interface for linear modeling of single channel microarray data
JM Wettenhall et al.
BIOINFORMATICS (2006)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Galectins as modulators of tumour progression
FT Liu et al.
NATURE REVIEWS CANCER (2005)
Reclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention
A Catalano et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy
RS Pruthi et al.
BJU INTERNATIONAL (2004)
Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint
GJPL Kops et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Malignant pleural mesothelioma - Update, current management, and newer therapeutic strategies
M Pistolesi et al.
CHEST (2004)
Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma
A Baldi et al.
THORAX (2004)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer
NK Altorki et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma - A multicentric phase II study
AG Favaretto et al.
CANCER (2003)
Identification of a novel cell cycle regulated gene, HURP, overexpressed in human hepatocellular carcinoma
AP Tsou et al.
ONCOGENE (2003)
The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells
A Baldi et al.
ONCOGENE (2002)
A new mathematical model for relative quantification in real-time RT-PCR
MW Pfaffl
NUCLEIC ACIDS RESEARCH (2001)
MgcRacGAP is involved in cytokinesis through associating with mitotic spindle and midbody
K Hirose et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
p21Waf1/Cip1/Sdi1-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells
BD Chang et al.
ONCOGENE (2000)
分享论文
